NKX is a prostate-specific tumor suppressor gene and loss of a single allele may predispose to prostate carcinogenesis (1). Studies have shown that the onset of MYC overexpression and the subsequent development of prostatic intraepithelial neoplasia coincide with this reduction in NKX (2). Over-expression of MYC has been reported as an early oncogenic event driving prostatic cancer progression (3). Data shows that NKX expression is highly, but not exclusively, specific for the prostate. Loss of NKX3.1 expression is strongly associated with hormone-refractory disease and advanced tumor stage in prostate cancer (4).